Literature DB >> 24752651

ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

Aijaz Parray1, Hifzur R Siddique, Jacquelyn K Kuriger, Shrawan K Mishra, Johng S Rhim, Heather H Nelson, Hiroyuki Aburatani, Badrinath R Konety, Shahriar Koochekpour, Mohammad Saleem.   

Abstract

High-risk populations exhibit early transformation of localized prostate cancer (CaP) disease to metastasis which results in the mortality of such patients. The paucity of knowledge about the molecular mechanism involved in acquiring of metastatic behavior by primary tumor cells and non-availability of reliable phenotype-discriminating biomarkers are stumbling blocks in the management of CaP disease. Here, we determine the role and translational relevance of ROBO1 (an organogenesis-associated gene) in human CaP. Employing CaP-progression models and prostatic tissues of Caucasian and African-American patients, we show that ROBO1 expression is localized to cell-membrane and significantly lost in primary and metastatic tumors. While Caucasians exhibited similar ROBO1 levels in primary and metastatic phenotype, a significant difference was observed between tumor phenotypes in African-Americans. Epigenetic assays identified promoter methylation of ROBO1 specific to African-American metastatic CaP cells. Using African-American CaP models for further studies, we show that ROBO1 negatively regulates motility and invasiveness of primary CaP cells, and its loss causes these cells to acquire invasive trait. To understand the underlying mechanism, we employed ROBO1-expressing/ROBO1-C2C3-mutant constructs, immunoprecipitation, confocal-microscopy and luciferase-reporter techniques. We show that ROBO1 through its interaction with DOCK1 (at SH3-SH2-domain) controls the Rac-activation. However, loss of ROBO1 results in Rac1-activation which in turn causes E-Cadherin/β-catenin cytoskeleton destabilization and induction of cell migration. We suggest that ROBO1 is a predictive biomarker that has potential to discriminate among CaP types, and could be exploited as a molecular target to inhibit the progression of disease as well as treat metastasis in high-risk populations such as African-Americans.
© 2014 UICC.

Entities:  

Keywords:  African-American; ROBO1; indolent; metastatic; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24752651      PMCID: PMC4610361          DOI: 10.1002/ijc.28919

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Authors:  Shaniece Theodore; Starlette Sharp; Jianjun Zhou; Timothy Turner; Hongzhen Li; Jun Miki; Youngmi Ji; Vyomesh Patel; Clayton Yates; Johng S Rhim
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

Review 2.  Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy.

Authors:  Sibaji Sarkar; Sarah Goldgar; Shannon Byler; Shoshana Rosenthal; Sarah Heerboth
Journal:  Epigenomics       Date:  2013-02       Impact factor: 4.778

Review 3.  Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Authors:  Lata Chandi Thatai; Mousumi Banerjee; Zongshan Lai; Ulka Vaishampayan
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

Review 4.  Prostate cancer in black and white Americans.

Authors:  Sreekanth Reddy; Marc Shapiro; Ronald Morton; Otis W Brawley
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

5.  Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.

Authors:  Mohammad Saleem; Imtiyaz Murtaza; Rohinton S Tarapore; Yewseok Suh; Vaqar Mustafa Adhami; Jeremy James Johnson; Imtiaz Ahmad Siddiqui; Naghma Khan; Mohammad Asim; Bilal Bin Hafeez; Mohammed Talha Shekhani; Benyi Li; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2009-02-20       Impact factor: 4.944

Review 6.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22

Review 7.  New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration.

Authors:  A J M Mol; A A Geldof; G A Meijer; H G van der Poel; R J A van Moorselaar
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-23       Impact factor: 4.553

8.  Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA.

Authors:  Shahriar Koochekpour; Grace A Maresh; Adrienne Katner; Kitani Parker-Johnson; Tae-Jin Lee; Francine E Hebert; Yuan S Kao; John Skinner; Walter Rayford
Journal:  Prostate       Date:  2004-07-01       Impact factor: 4.104

9.  Src activates Abl to augment Robo1 expression in order to promote tumor cell migration.

Authors:  P Raaj Khusial; Bhaskar Vadla; Harini Krishnan; Trudy F Ramlall; Yongquan Shen; Hitoshi Ichikawa; Jian-Guo Geng; Gary S Goldberg
Journal:  Oncotarget       Date:  2010-07

10.  Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.

Authors:  Ashraf Dallol; Eva Forgacs; Alonso Martinez; Yoshitaka Sekido; Rosemary Walker; Takeshi Kishida; Pamela Rabbitts; Eamonn R Maher; John D Minna; Farida Latif
Journal:  Oncogene       Date:  2002-05-02       Impact factor: 9.867

View more
  20 in total

1.  Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer.

Authors:  Hui-Yi Lin; Chia-Ho Cheng; Dung-Tsa Chen; Y Ann Chen; Jong Y Park
Journal:  Transl Cancer Res       Date:  2016-10       Impact factor: 1.241

2.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors:  Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal:  Cancer Rep (Hoboken)       Date:  2018-12-13

3.  ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients.

Authors:  Rolando A R Villacis; Francine B Abreu; Priscila M Miranda; Maria A C Domingues; Dirce M Carraro; Erika M M Santos; Victor P Andrade; Benedito M Rossi; Maria I Achatz; Silvia R Rogatto
Journal:  Tumour Biol       Date:  2015-10-01

4.  Robo1 promotes angiogenesis in hepatocellular carcinoma through the Rho family of guanosine triphosphatases' signaling pathway.

Authors:  Jian-Yang Ao; Zong-Tao Chai; Yuan-Yuan Zhang; Xiao-Dong Zhu; Ling-Qun Kong; Ning Zhang; Bo-Gen Ye; Hao Cai; Dong-mei Gao; Hui-Chuan Sun
Journal:  Tumour Biol       Date:  2015-05-29

5.  Analysis of K-Ras Interactions by Biotin Ligase Tagging.

Authors:  Christopher Ritchie; Andrew Mack; Logan Harper; Ayna Alfadhli; Philip J S Stork; Xiaolin Nan; Eric Barklis
Journal:  Cancer Genomics Proteomics       Date:  2017 Jul-Aug       Impact factor: 4.069

6.  ROBO1 protein expression is independently associated with biochemical recurrence in prostate cancer patients who underwent radical prostatectomy in Asian patients.

Authors:  Sang Hoon Kim; Tae-Jung Kim; Dongho Shin; Kyung Jae Hur; Sung-Hoo Hong; Ji Youl Lee; U-Syn Ha
Journal:  Gland Surg       Date:  2021-10

Review 7.  Race and prostate cancer: genomic landscape.

Authors:  Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag
Journal:  Nat Rev Urol       Date:  2022-08-09       Impact factor: 16.430

8.  Evaluation of active Rac1 levels in cancer cells: A case of misleading conclusions from immunofluorescence analysis.

Authors:  Martin J Baker; Mariana Cooke; Gabriel Kreider-Letterman; Rafael Garcia-Mata; Paul A Janmey; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

9.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Authors:  David C Wedge; Gunes Gundem; Thomas Mitchell; Dan J Woodcock; Inigo Martincorena; Mohammed Ghori; Jorge Zamora; Adam Butler; Hayley Whitaker; Zsofia Kote-Jarai; Ludmil B Alexandrov; Peter Van Loo; Charlie E Massie; Stefan Dentro; Anne Y Warren; Clare Verrill; Dan M Berney; Nening Dennis; Sue Merson; Steve Hawkins; William Howat; Yong-Jie Lu; Adam Lambert; Jonathan Kay; Barbara Kremeyer; Katalin Karaszi; Hayley Luxton; Niedzica Camacho; Luke Marsden; Sandra Edwards; Lucy Matthews; Valeria Bo; Daniel Leongamornlert; Stuart McLaren; Anthony Ng; Yongwei Yu; Hongwei Zhang; Tokhir Dadaev; Sarah Thomas; Douglas F Easton; Mahbubl Ahmed; Elizabeth Bancroft; Cyril Fisher; Naomi Livni; David Nicol; Simon Tavaré; Pelvender Gill; Christopher Greenman; Vincent Khoo; Nicholas Van As; Pardeep Kumar; Christopher Ogden; Declan Cahill; Alan Thompson; Erik Mayer; Edward Rowe; Tim Dudderidge; Vincent Gnanapragasam; Nimish C Shah; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Teague; Steven Hazell; Cathy Corbishley; Johann de Bono; Gerhardt Attard; William Isaacs; Tapio Visakorpi; Michael Fraser; Paul C Boutros; Robert G Bristow; Paul Workman; Chris Sander; Freddie C Hamdy; Andrew Futreal; Ultan McDermott; Bissan Al-Lazikani; Andrew G Lynch; G Steven Bova; Christopher S Foster; Daniel S Brewer; David E Neal; Colin S Cooper; Rosalind A Eeles
Journal:  Nat Genet       Date:  2018-04-16       Impact factor: 38.330

10.  High SEC61G expression predicts poor prognosis in patients with Head and Neck Squamous Cell Carcinomas.

Authors:  Leifeng Liang; Qingwen Huang; Mei Gan; Liujun Jiang; Haolin Yan; Zhan Lin; Haisheng Zhu; Rensheng Wang; Kai Hu
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.